COMPASS Pathways (NASDAQ:CMPS) Issues Quarterly Earnings Results

COMPASS Pathways (NASDAQ:CMPS) posted its quarterly earnings results on Thursday. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports.

COMPASS Pathways Stock Up 0.3 %

NASDAQ CMPS opened at $3.93 on Friday. The firm has a market cap of $268.89 million, a PE ratio of -1.79 and a beta of 2.28. COMPASS Pathways has a one year low of $3.16 and a one year high of $12.57. The stock’s 50 day simple moving average is $4.06 and its 200 day simple moving average is $5.26. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CMPS shares. Canaccord Genuity Group dropped their target price on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday. HC Wainwright dropped their target price on COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Maxim Group dropped their target price on COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Stifel Nicolaus started coverage on COMPASS Pathways in a report on Thursday. They issued a “buy” rating and a $11.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $21.83.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.